Evidence map›Paper›PMID 41841492›Full record

ArticleNucleic acids research2026

Structural and functional insights into the adenosine deaminase of the type III-B CRISPR-Cas system.

Zhaoxing Li, Jianping Kong, Wanqian Wu, Yan Duan, Ziyi Zhu, Chenyang Hua, Purui Yan, Chen Cao, Xu Cao, Yibei Xiao and 2 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhaoxing LiState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.ORCID 0000-0002-6928-9856
Jianping KongState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Wanqian WuState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Yan DuanSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Ziyi ZhuState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Chenyang HuaDepartment of Biochemistry, School of Life Science and Technology, China, Pharmaceutical University, Nanjing 211198, China.
Purui YanState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Chen CaoDepartment of Biochemistry, School of Life Science and Technology, China, Pharmaceutical University, Nanjing 211198, China.
Xu CaoShanghai Frontiers Science Center for Drug Target Identification and Delivery, and the Engineering Research Center of Cell and Therapeutic Antibody of the Ministry of Education, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
Yibei XiaoState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.ORCID 0000-0003-4716-5526
Meiling LuDepartment of Biochemistry, School of Life Science and Technology, China, Pharmaceutical University, Nanjing 211198, China.
Meirong ChenState Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.

Funding

Basic Research Program of Jiangsu BK20250200Basic Research Program of Jiangsu SBK2024010634China Pharmaceutical University SKLNMZZ2024JS31Fundamental Research Funds for the Central Universities 2632025TD02National Key Research and Development Program of China 2021ZD0203400National Key Research and Development Program of China 2023YFC3402300National Natural Science Foundation of China 32271330National Natural Science Foundation of China 32471316National Natural Science Foundation of China 82304614National Natural Science Foundation of China 82373892National Natural Science Foundation of China 82473977Project Program of State Key Laboratory of Natural MedicinesState Key Laboratory of Natural Medicines
6 · The paper itself

Abstract

Type III CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins) systems confer antiviral immunity via cyclic oligoadenylate (cOA) signaling. Here, we elucidate a cooperative bacterial defense strategy involving two cOA-activated CRISPR-associated Rossmann fold (CARF)-containing effectors, adenosine deaminase CAAD and ribonuclease Csx1, in Thermoanaerobaculum aquaticum. Genomic analyses indicate widespread co-occurrence of CRISPR-associated adenosine deaminase (CAAD) with ancillary CARF-containing effectors in type III CRISPR systems, suggesting that multiple CARF-containing proteins may contribute to a coordinated cOA-dependent defense. Biochemical and structural studies reveal the intrinsic dynamics of CAAD hexamer, and demonstrate that cA4/cA6 binding stabilizes CAAD hexamers, triggering metal-ion-dependent conversion of ATP into inosine triphosphate. Concurrently, the downstream Csx1 is exclusively activated by cA4 to cleave single-stranded RNA. Strikingly, we found that both effectors are capable of degrading cA4, suggesting that this CAAD-Csx1 pair may be cross-regulated and achieve immunity through a dual-targeting mechanism: in response to infection, Csx1 degrades viral RNA while CAAD disrupts nucleotide metabolism via ATP deamination, which can be relieved via cA4 degradation when infection has been eliminated. This study proposes an enhanced defense mechanism through coordinated activation and regulation of multiple CRISPR effectors by a single signaling molecule, unveiling unprecedented complexity in CRISPR immunoregulation.

Indexed as

Adenosine DeaminaseBacterial ProteinsCRISPR-Associated ProteinsCRISPR-Cas SystemsAdenine NucleotidesAdenosine TriphosphateModels, MolecularOligoribonucleotidesRibonucleasesAdenine NucleotidesAdenosine DeaminaseAdenosine TriphosphateBacterial ProteinsCRISPR-Associated ProteinsOligoribonucleotidesRibonucleases

Identifiers

PMID41841492
PMCPMC12993439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.